A double blind randomized placebo controlled pilot study of the serum amyloid P com[p]onent binding inhibitor CPHPC [RO 638695] in patients with osteoarthritis to assess tolerability, safety, and efficacy over a period of 24 weeks. Particular items discussed...
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2005
At a glance
- Drugs RO 638695 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- 19 Jul 2005 New trial record.